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Edited by Ulf-Ingo Fl€uggeAbstract Glucagon-like peptide-1 (7-36) amide (GLP-1) is the
most potent physiological insulinotropic hormone in humans. We
produced large amounts of a GLP-1 analogue, [Ser8, Gln26,
Asp34]-GLP-1, which is resistant to trypsin-digestion, as part
of a chimeric rice seed storage protein, a 26 kDa globulin, in
genetically modiﬁed rice seeds. Junction sites between GLP-1
analogue and globulin were replaced by tryptic cleavage sites.
The highest level of GLP-1 analogue accumulation was 20–
50 lg per seed. We found that GLP-1 analogue derived from
trypsin-digested genetically modiﬁed rice seeds stimulated insulin
secretion from a mouse pancreatic beta-cell line, MIN6.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Glucagon-like peptide-1 (GLP-1) is a potent blood glucose-
lowering hormone that stimulates the secretion of insulin from
pancreatic beta-cells [1,2]. Since the half-life of GLP-1 by sub-
cutaneous injections is very short [3,4], novel GLP-1 analogues
or a synthetically produced GLP-1 agonist, Exendin-4 with a
binding aﬃnity to the pancreatic GLP-1 receptor similar to
that of GLP-1 have been developed [5]. Another approach in-
cludes the use of dipeptidylpeptidase-IV(DPPIV) inhibitors to
augment the endogenous active GLP-1 [6] that was instantly
cleaved by DPPIV at Ala8. We describe here a new approach
for the exogenous administration of GLP-1 analogue, in which
patients with Type 2 diabetes eat genetically modiﬁed rice
seeds with elevated levels of the GLP-1 analogue.
Medical molecular farming has been an attractive possible
option for the production of recombinant biopharmaceuti-
cals in contrast to methods using animal cells, bacteria,
and fungi [7–9]. On the other hand, the stable storage of
small peptides can be very diﬃcult to achieve in genetically
modiﬁed plant systems. Vandekerckhove et al. [10] reported*Corresponding author. Fax: +81 29 838 8397.
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peptide) fusion protein was produced in the seeds of genet-
ically modiﬁed Arabidopsis and oilseed. In this study, we
constructed a chimeric globulin seed storage protein gene.
In this DPPIV- and trypsin-resistant GLP-1 analogue, the
DPPIV sensitive site Ala8 was changed to Ser8 and two tryp-
tic cleavage sites, Lys26 and Lys34, were changed to Gln26
and to Asp34, respectively. This construct was inserted into
the variable region of the rice globulin gene under control
of the native globulin promoter. To release the active
GLP-1 analogue in the small intestine, tryptic cleavage sites
were introduced to both ends of the GLP-1 analogue gene.
We generated Genetically modiﬁed rice seeds were generated
using the MAT-vector system [11,12].
In the present report, rice seeds containing the GLP-1 ana-
logue as part of a chimeric globulin seed storage protein were
digested with trypsin and the trypsin-resistant GLP-1 analogue
was extracted. The content of the GLP-1 analogue that had
been accumulated was measured by radioimmunoassays. In vi-
tro studies of a mouse pancreatic beta-cell line demonstrated
that GLP-1 analogue from chimeric globulin stimulated insu-
lin secretion in a mouse pancreatic beta-cell line, MIN6 [13].
These ﬁndings suggest that the consumption of genetically
modiﬁed rice seeds containing elevated levels of the GLP-1
analogue may control blood glucose levels in humans.2. Materials and methods
2.1. Plasmid construction
Plasmids were constructed using standard recombinant technique
[14]. The codon-optimized GLP-1 analogue gene was synthesized by
PCR based on the designed sequence using long sense and antisense
oligonucleotides with overlaps of 18 nt as primers using high ﬁdelity
Taq polymerase. This GLP-1 analogue gene was introduced between
amino acid positions 109 and 110 of 26 kDa globulin cDNA by two-
overlap extension PCR method, and then fused to 980 bp globulin
promoter. The EcoRI–Sse8387I fragment of Glb promoter-globulin
(GLP-1 analogue)-Nos terminator was ligated into the EcoRI–
Sse8387I site of pTL7 to produce pGlbGLP. The KpnI fragment of
the CaMV35S promoter-hph-Nos terminator was ligated into the inter-
nal KpnI site of the R/RS cassette of pNPI130PUC to produce
pNPI130Hm [12]. The Sse8387I fragment of pNPI130Hm was cloned
into the Sse8387I site of pGlbGLP to produce pGlbGLP130Hm.
2.2. Transformation
This pGlbGLP130Hm was introduced into Agrobacterium tumefac-
iens strain EHA105 by electroporation [15].blished by Elsevier B.V. All rights reserved.
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ing to the modiﬁed procedure described in [16]. Mature rice seeds (Or-
yza sativa L.cv. Nipponbare) were sterilized in 75% (v/v) sodium
hypochloride for 30 min and washed thoroughly in sterilized water.
The sterilized seeds were germinated on N6CL2 medium (N6 basal,
N6 vitamins, sucrose 30 g/l, casamino acid 0.3 g/l, proline 2.8 g/l, 2,4-
D 1.0 mg/l, gelrite 4 g/l) for 5 days at 30 C light and were used as
explants for an Agrobacterium-mediated transformation. Infected-
seedlings were co-cultivated on N6Cl2CO medium (N6 basal, N6
vitamins, sucrose 30 g/l, glucose 10 g/l, casamino acid 0.3 g/l, proline
2.8 g/l, 2,4-D 1.0 mg/l, acetosyryngone 10 mg/l, gelrite 4 g/l) for 3 days
at 28 C in the dark. Co-cultivated seedlings were washed and trans-
ferred to N6Cl2TCH25 medium (N6 basal, N6 vitamins, sucrose
30 g/l, casamino acid 0.3 g/l, proline 2.8 g/l, 2,4-D 2.0 mg/l, carbenicillin
0.5 g/l, hygromycin 25 mg/l, gelrite 4 g/l) for 7 days at 30 C in the light
and scutellum tissues were transferred to N6Cl4TCH25 medium (N6
basal, N6 vitamins, sucrose 30 g/l, casamino acid 0.3 g/l, proline
2.8 g/l, 2,4-D 4.0 mg/l, carbenicillin 0.5 g/l, hygromycin 25 mg/l, gelrite
4 g/l) for 7 days at 30 C in the light. Then, scutellum tissues were cul-
tured onMSRCmedium (MS basal, MS vitamins, sucrose 30 g/l, sorbi-
tol 30 g/l, casamino acid 2 g/l, carbenicillin 0.5 g/l, gelrite 4 g/l) at 30 C
in the light. Regenerated shoots were transplanted to MS medium.
2.3. DNA analysis
Genomic DNA samples were prepared from in vitro grown leaves
following the suppliers instructions of DNAeasy Plant System (Qia-
gen) and used as template for PCR analysis. For the GLP-1 analogue
gene, two primers were the GLP3-1 primer 5 0-ggatccatggctag-
caaggtcgtc-30 and the GLP3-3 5 0-gatcactatctcgttgcatgcaacac-3 0
(Fig. 1B). PCRs were performed with KOD-Plus polymerase in a
20-ll reaction following the suppliers instructions (TOYOBO, Japan).
2.4. Protein extraction and Western blot analysis
Each mature seed was ground to a ﬁne powder by the Multi-beads
shocker (Yasui Kikai, Osaka) as described [17]. Seven hundred micro-
litres of SDS–urea solution (4% SDS, 8 M urea, 5% 2-mercap-
toethanol, 50 mM Tris–HCl (pH 6.8), and 20% (v/v) glycerol) was
added to a seed powder and the protein was extracted by vortexing vig-
orously for 1 h at room temperature. After centrifugation, total protein
extracts of the supernatant were applied to SDS–PAGE. Proteins were
transferred to a nitrocellulose ﬁlter by semidry blotting. The chimericpGlbGLP130Hm
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Fig. 1. Schematic structure of the T-DNA of pGlbGLP130Hm used
for Agrobacterium-mediated rice transformation. (A) Nucleotides and
amino acid sequence of the cleavage site for trypsin. The underlined
lysine and arginine residues are cleaved with trypsin. (B) The
pGlbGLP130Hm plasmid vector for a chimeric GLP-1/globulin. The
chimeric GLP-1/globulin gene was cloned into the outside of an
excised R/RS cassette. The cassette has the ipt, hph and R genes
between two directly oriented RS sequence. RB, right border; LB, left
border; Glb-P, promoter of rice globulin gene; NT, polyadenylation
sequence of nopaline synthase gene; t, polyadenylation sequence of ipt
gene; NP, promoter of nopaline synthase gene; ipt, isopentenyltrans-
ferase gene; hph, hygromycin phosphotransferase gene; R, recombinase
gene of yeast site-speciﬁc recombination R/RS system; RS, recombi-
nation sequence of R/RS.GLP-1 analogue/globulin proteins were detected by the anti-GLP-1
analogue monoclonal antibody followed by antimouse IgG, coupled
to alkaline phosphatase.
2.5. Protein extraction and radioimmunoassay
Mature grains were ground with a mortar and pestle and defatted
with chilled acetone. After centrifugation, the pellet was dried up.
Then, the chimeric globulin seed storage protein was extracted in
0.025 N NaOH for 24 h at 4 C. The extracted protein was neutralized
with HCl and treated with trypsin for 2 h at 37 C. The trypsin-di-
gested sample was extracted with ethanol (ﬁnal concentration,
74.6%). The supernatant was collected and dried up with a centrifuging
evaporator and supplied to the radioimmunoassay for quantitative
analysis and the in vitro insulin secretion assay. The radioimmunoas-
say was carried out using by the GLP-1 (Total) RIA Kit (LINCO)
according to the suppliers procedure as a standard of [Ser8, Gln26,
Asp34]-GLP-1.
2.6. Assay of insulin secretion
After inoculation in the medium containing 10 mM glucose and the
trypsin-digested sample for 45 min at 37 C, the content of insulin in
the medium was measured with the Insulin kit (Shibayagi, AKRIN-
011).3. Results
3.1. Construction of chimeric GLP-1 analogue/globulin protein
expression vector
We used a DNA encoding 30 amino acid residues corre-
sponding to peptide [Ser8, Gln26, Asp34]-GLP-1 (7-36). The
GLP-1 analogue gene was inserted into the variable region
of the rice 26 kDa globulin gene between residues 109 and
110 (Fig. 1A) [18]. Furthermore, two junction sites of GLP-1
analogue and globulin were replaced by lysine and arginine
residues, respectively, for trypsin digestion (Fig. 1A). In the
present study, we used the new Hm/MAT-vector into which
the hph gene and ipt gene [19,20] were inserted into the internal
region between two directly oriented recombination sequences
(RS) (Fig. 1B) [21]. The hph gene has been used as a selectable
marker gene in addition to the ipt gene, and is eliminated from
transgenic cells together with the recombinase gene and the ipt
gene. Therefore, the Hm/MAT-vector can generate selectable
marker-free genetically modiﬁed rice seeds.
3.2. GLP-1 accumulation in seeds of genetically modiﬁed rice
Six independent primary genetically modiﬁed rice plants (T0)
were regenerated and cultivated in a greenhouse. These lines
were positive when analyzed for the presence of the chimeric
GLP-1 analogue/globulin gene by PCR analysis (data not
shown). All of them were fertile and seeded. For each T0 line,
10 seeds were horizontally cut into two parts: the grain and
the embryo attached to the grain. The accumulation of chime-
ric GLP-1 analogue/globulin was determined by Western blot
analysis in the grains in the T0 line (Fig. 2). Very high levels of
accumulated GLP-1 analogue/globulin were found in all lines
(Fig. 2, lanes 1–6).
The grain halves from four genetically modiﬁed seeds from
each T0 line were subjected to radioimmunoassay analysis
(Fig. 3). No GLP-1 analogue accumulation was detected in
the grains of untransformed rice seeds (Fig. 3, lane 7). The
highest level of GLP-1 analogue accumulation was observed
in line 185-62401 (Fig. 3, lane 1). Independent grains from line
185-62401 accumulated the GLP-1 analogue in amounts rang-
ing from 20 to 50 lg/20 mg seed. We also measured, the
Table 1
Stimulation of insulin secretion by GLP-1 analogue extracted from
genetically modiﬁed rice seeds in MIN6 cell
Line GLP-1 analogue
content (M)
Insulin
release (ng/ml)
185-62401 9.4 · 1010 989.4
185-70116 9.7 · 1010 734.3
Untransformed ND
Synthesized [Ser8, Gln26, Asp34]-
GLP-1 analogue
1.0 · 109 594.3
Fig. 2. Western blot analysis of extracts of T0 rice seed transformed
with the chimeric GLP-1/globulin gene. (A) Soluble proteins extracted
from a mature seed were fractionated by SDS–PAGE. The arrow
indicates the chimeric GLP-1/globulin protein. (B) Western blot
analysis was performed with anti-GLP-1 monoclonal antibody. Lanes
1–6, T0 seed of genetically modiﬁed rice transformed with the
pGlbGLP130Hm; lane 7, untransformed rice; lane 8, T3 seed of
genetically modiﬁed rice transformed with the conventional vector.
Fig. 3. The accumulation level of GLP-1 analogue in mature seed of
T0 genetically engineered rice. The chimeric rice globulin/GLP-1
storage protein in mature seeds was cleaved with trypsin and GLP-1
analogue was extracted. The content of GLP-1 analogue was deter-
mined with radioimmunoassay. The content of four PCR-positive
seeds per rice line, including both hemizygous and homozygous seeds,
were plotted on the graph. Lanes 1–6, T0 seed of genetically modiﬁed
rice transformed with the pGlbGLP130Hm; lane 7, untransformed
rice; lane 8, T3 seed of genetically modiﬁed rice transformed with the
conventional vector.
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modiﬁed rice seeds produced by a conventional binary vector
system (Fig. 2, lane 8 and Fig. 3, lane 8). This elite line was se-
lected from 50 genetically modiﬁed rice lines regenerated
from hygromycin-resistant calli. Independent grains from this
elite line accumulated the GLP-1 analogue in amounts ranging
from 10 to 20 lg/20 mg seed (Fig. 3, lane 8). These results
indicate that the Hm/MAT-vector system tends to increase
the accumulation level of the chimeric GLP-1 analogue/globu-
lin protein.3.3. Stimulating eﬀect of GLP-1 analogue as part of a chimeric
globulin protein on insulin secretion from MIN6 cells
We measured insulin secretion levels of 10 T1 grains of the
185-62401 line, the 185-70116 line and untransformed rice in
a mouse pancreatic beta-cell line, MIN6 [13]. No biological
activity of GLP-1 analogue was detected in grains of untrans-
formed rice seeds. Meanwhile, the 185-62401 and 185-70116
lines showed biological activity in insulin secretion at levels
of 989.4 and 734.3 ng/ml (Table 1). The biological activity of
synthetic [Ser8, Gln26, Asp34]-GLP-1 was slightly less than that
of native GLP-1 (7-36) amide (data not shown).4. Discussion
Type 1 diabetes generally results from an inability of the im-
mune system to recognize glutamic acid decarboxylase (GAD),
insulin, and other related protein [22]. On the other hand, Type
2 diabetes is associated with lifestyle. For therapeutic use in
Type 1 diabetes, genetically modiﬁed plants have been gener-
ated that express autoantigens of insulin-dependent diabetes
mellitus (IDDM), GAD [23] and insulin linked to the C-termi-
nus of the cholera toxin B subunit (CTB-INS) [24]. These re-
ports indicated an eﬀective suppression of pancreatic islet
inﬂammation (insulitis) in the nonobese diabetic (NOD)
mouse. In this report, we describe genetically modiﬁed rice
seeds containing an GLP-1 analogue as part of the rice seed
storage protein globulin for possible application to patients
with Type 2 diabetes. The in vitro test demonstrates that these
genetically modiﬁed rice seeds could stimulate insulin secretion
from a mouse pancreatic beta-cell line (Table 1).
Many genetically modiﬁed plants have been reported for use
in molecular farming [7–9]. In particular, genetically modiﬁed
seeds are very cost-eﬃcient hosts. Seed storage proteins are
very stable for over one year [25]. We conﬁrmed that the
GLP-1 analogue that had been accumulated in genetically
modiﬁed rice seeds retained its biological activity for over
one year (data not shown). The puriﬁcation costs are also rea-
sonable because seeds do not contain toxic compounds such as
alkaloids. Seed production costs are also very low because
agricultural processing procedures can be used. When materi-
als are produced with a conventional transformation vector
system, the genome also contains selectable marker genes,
e.g., antibiotic- or herbicide-resistance genes. In this paper,
we used the MAT-vector system to generate genetically modi-
ﬁed rice seeds. Since the MAT-vector system eliminates the
selectable marker gene, we can produce selectable marker-free
genetically modiﬁed rice seeds [12]. When patients are pro-
vided with genetically modiﬁed biopharmaceutical foods, a
selectable marker-free system is needed to address public con-
cerns and for commercialization as reported in the Codex
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dard Programme [26].
We constructed here a chimeric globulin protein gene that
contained GLP-1 analogue gene (Fig. 1). High amounts of
GLP-1 analogue were detected by Western blot analysis in
all of the genetically modiﬁed rice seeds (Fig. 2). A RIA assay
showed that the highest accumulation of the GLP-1 analogue
was 50 lg/20 mg seed (Fig. 3). This level is approximately
ﬁve times higher compared to genetically modiﬁed rice seeds
regenerated from antibiotic-resistant scutellum calli trans-
formed with a conventional selection system (Fig. 3). While
the mechanism of this high level of accumulation is unclear,
the MAT-vector system might have a beneﬁcial eﬀect on gene
expression and protein accumulation.
The chimeric GLP-1 analogue/globulin protein was ex-
tracted from mature seeds of genetically modiﬁed rice and trea-
ted with trypsin. In the present in vitro study, the GLP-1
analogue released from chimeric globulin proteins by trypsin
digestion stimulated the insulin secretion from the pancreatic
beta-cell line MIN6 (Table 1). This observation led suggests
that oral administration of genetically modiﬁed rice seeds con-
taining GLP-1 analogue may be able to stimulate insulin secre-
tion and lower blood glucose levels. Presently, its eﬀect on the
production of cAMP, the concentration of released insulin and
blood glucose in vivo is investigated.
In this study, rice seeds as biopharmaceutical foods and biore-
actors for producingGLP-1 analogue were used, since rice is the
most important food crop in Asia and is the most eﬀective plant
for cultivation. This rice seed-based systemmay also be suitable
for producing other biopharmaceutical peptides and proteins.
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